Group 1 - SpyGlass Pharma, a biotechnology company focused on chronic eye disease treatments, is in the third phase of clinical trials and has announced its IPO terms, planning to issue 9.4 million shares at a price range of $15-17 per share, aiming to raise $150 million [1] - The fully diluted market capitalization of SpyGlass Pharma is projected to reach $549 million based on the midpoint of the proposed price range [1] - The company's core product is the Bimatoprost Implantable Lens System (BIM-IOL), designed to lower elevated intraocular pressure in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) during routine cataract surgery [1] Group 2 - SpyGlass Pharma was founded in 2019 and plans to list on NASDAQ under the ticker symbol "SGP" [2] - The underwriters for the IPO include Jefferies, Leerink Partners, Citigroup, and Stifel [2]

Registration No. 333-292779 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 As filed with the Securities and Exchange Commission on January 29, 2026. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SpyGlass Pharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 83-3044245 (I.R.S. Employer Identification ...

Core Viewpoint - SpyGlass Pharma, Inc. has filed to raise $100 million in an IPO of its common stock, with the final amount subject to change [1] Group 1: Company Overview - SpyGlass Pharma, Inc. is preparing for an initial public offering (IPO) to raise $100 million [1] Group 2: IPO Insights - Donovan Jones, an IPO research specialist with 15 years of experience, leads the investing group IPO Edge, which provides actionable information on growth stocks and IPOs [1] - IPO Edge offers resources including first-look IPO filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a guide to IPO investing [1]

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SpyGlass Pharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) Delaware 3841 83-3044245 (I.R.S. Employer Identification Number) 27061 Aliso Creek Rd., Suite 100 Aliso Viejo, Ca ...